PDF(Pubmed)
Abstract：
UNASSIGNED: In this research, we investigated any possible effect of receiving hyperbaric oxygen therapy (HBOT) or risperidone on the core symptoms of autism in children diagnosed with autism spectrum disorder (ASD).
UNASSIGNED: This study was a randomized, controlled clinical trial in Minia and Assiut University hospitals in Egypt with three parallel groups. One hundred and eighty children with autism, aged 5-8 years were divided into three equal groups (n=60). Group 1 (G1) received 40 sessions of HBOT within two months, group 2 (G2) received risperidone (dose: 0.25 mg per day in children weighing less than 20 kg and 0.5 mg per day in cases weighing more) for six months, and group 3 (G3) as the control group, received a placebo for six months. The assessment was done using childhood autism rating scale (CARS) and autism treatment evaluation checklist (ATEC) at the beginning of the study (baseline) and after one year.
UNASSIGNED: The mean total CARS and ATEC scores significantly decreased (improved) by varying degrees in the three groups after a year of follow-up compared to the baseline scores, but the best results were found in G1, G2, and G3, respectively.
UNASSIGNED: Using HBOT or risperidone is effective in treating the core symptoms of autism in children diagnosed with autism spectrum disorder, but using HBOT gives better results than risperidone therapy.
UNASSIGNED: Non-pharmacologic therapy can be used for the treatment of the core symptoms of autism.Both hyperbaric oxygen therapy and risperidone reduce the core symptoms of autism.Hyperbaric oxygen therapy gives better effects than risperidone in reducing the core symptoms of autism.
UNASSIGNED: Since the long-term use of drug therapy in children with autism leads to the occurrence of side effects in addition to the difficulty in complying with the drugs for long-term use, efforts have begun to use non-traditional alternative treatments, such as hyperbaric oxygen therapy. The current study assessed the therapeutic effect of hyperbaric oxygen therapy and risperidone on the core symptoms of autism. The results revealed that both hyperbaric oxygen therapy and risperidone reduced the core symptoms of autism, but hyperbaric oxygen therapy gave better therapeutic results than risperidone.
UNASSIGNED: This study was a randomized, controlled clinical trial in Minia and Assiut University hospitals in Egypt with three parallel groups. One hundred and eighty children with autism, aged 5-8 years were divided into three equal groups (n=60). Group 1 (G1) received 40 sessions of HBOT within two months, group 2 (G2) received risperidone (dose: 0.25 mg per day in children weighing less than 20 kg and 0.5 mg per day in cases weighing more) for six months, and group 3 (G3) as the control group, received a placebo for six months. The assessment was done using childhood autism rating scale (CARS) and autism treatment evaluation checklist (ATEC) at the beginning of the study (baseline) and after one year.
UNASSIGNED: The mean total CARS and ATEC scores significantly decreased (improved) by varying degrees in the three groups after a year of follow-up compared to the baseline scores, but the best results were found in G1, G2, and G3, respectively.
UNASSIGNED: Using HBOT or risperidone is effective in treating the core symptoms of autism in children diagnosed with autism spectrum disorder, but using HBOT gives better results than risperidone therapy.
UNASSIGNED: Non-pharmacologic therapy can be used for the treatment of the core symptoms of autism.Both hyperbaric oxygen therapy and risperidone reduce the core symptoms of autism.Hyperbaric oxygen therapy gives better effects than risperidone in reducing the core symptoms of autism.
UNASSIGNED: Since the long-term use of drug therapy in children with autism leads to the occurrence of side effects in addition to the difficulty in complying with the drugs for long-term use, efforts have begun to use non-traditional alternative treatments, such as hyperbaric oxygen therapy. The current study assessed the therapeutic effect of hyperbaric oxygen therapy and risperidone on the core symptoms of autism. The results revealed that both hyperbaric oxygen therapy and risperidone reduced the core symptoms of autism, but hyperbaric oxygen therapy gave better therapeutic results than risperidone.
摘要：
■在这项研究中，我们调查了接受高压氧治疗(HBOT)或利培酮对被诊断为自闭症谱系障碍(ASD)的儿童自闭症核心症状的任何可能影响.
■这项研究是一项随机研究，在埃及的Minia和Assiut大学医院进行的对照临床试验，有三个平行组。一百八十名自闭症儿童，5-8岁被分为3组(n=60)。第1组(G1)在两个月内接受了40次HBOT，第2组（G2）接受利培酮（剂量：体重低于20kg的儿童每天0.25mg，体重更多的儿童每天0.5mg）治疗六个月，以第3组（G3）为对照组，服用安慰剂6个月.在研究开始时（基线）和一年后，使用儿童自闭症评定量表（CARS）和自闭症治疗评估清单（ATEC）进行评估。
■随访一年后，与基线评分相比，三组平均CARS和ATEC评分均有不同程度的显着下降（改善），但最好的结果分别在G1，G2和G3中发现。
■使用HBOT或利培酮可有效治疗被诊断患有自闭症谱系障碍的儿童的自闭症核心症状，但是使用HBOT比利培酮治疗效果更好。
■非药物疗法可用于治疗自闭症的核心症状。高压氧疗法和利培酮都可以减轻自闭症的核心症状。高压氧疗法在减轻自闭症的核心症状方面比利培酮效果更好。
■由于自闭症儿童长期使用药物治疗除了难以长期使用药物外，还会导致副作用的发生，已经开始努力使用非传统的替代疗法，如高压氧治疗。本研究评估了高压氧疗法和利培酮对自闭症核心症状的治疗效果。结果显示，高压氧治疗和利培酮都可以减轻自闭症的核心症状，但是高压氧疗法比利培酮治疗效果更好。
■这项研究是一项随机研究，在埃及的Minia和Assiut大学医院进行的对照临床试验，有三个平行组。一百八十名自闭症儿童，5-8岁被分为3组(n=60)。第1组(G1)在两个月内接受了40次HBOT，第2组（G2）接受利培酮（剂量：体重低于20kg的儿童每天0.25mg，体重更多的儿童每天0.5mg）治疗六个月，以第3组（G3）为对照组，服用安慰剂6个月.在研究开始时（基线）和一年后，使用儿童自闭症评定量表（CARS）和自闭症治疗评估清单（ATEC）进行评估。
■随访一年后，与基线评分相比，三组平均CARS和ATEC评分均有不同程度的显着下降（改善），但最好的结果分别在G1，G2和G3中发现。
■使用HBOT或利培酮可有效治疗被诊断患有自闭症谱系障碍的儿童的自闭症核心症状，但是使用HBOT比利培酮治疗效果更好。
■非药物疗法可用于治疗自闭症的核心症状。高压氧疗法和利培酮都可以减轻自闭症的核心症状。高压氧疗法在减轻自闭症的核心症状方面比利培酮效果更好。
■由于自闭症儿童长期使用药物治疗除了难以长期使用药物外，还会导致副作用的发生，已经开始努力使用非传统的替代疗法，如高压氧治疗。本研究评估了高压氧疗法和利培酮对自闭症核心症状的治疗效果。结果显示，高压氧治疗和利培酮都可以减轻自闭症的核心症状，但是高压氧疗法比利培酮治疗效果更好。
